Oligonol (Lychee fruit extract)

Oligonol is a patented lychee fruit extract standardized for low-molecular-weight oligomeric proanthocyanidins (OPCs), primarily derived from polyphenols such as catechin and epicatechin. It exerts antioxidant and anti-inflammatory effects by scavenging reactive oxygen species and inhibiting NF-κB-mediated cytokine signaling, with additional benefits for microcirculation via nitric oxide upregulation.

Origin & History

Oligonol is a branded, low-molecular-weight polyphenol extract derived primarily from lychee fruit (Litchi chinensis), with some formulations including green tea leaves in a 5:1 ratio. It is produced through a proprietary oligomerization process that breaks down high-molecular-weight lychee polyphenols into monomers and oligomers like catechins and procyanidins, standardized to >80% phenolic content.

Historical & Cultural Context

Lychee fruit, the primary source of Oligonol, has a long history of safe consumption in Asian diets. While the fruit itself is traditionally consumed, no specific traditional medicine systems or historical therapeutic uses are documented for Oligonol's concentrated polyphenols.

Health Benefits

• Antioxidant protection: Scavenges free radicals (DPPH/ABTS) with potency comparable to ascorbic acid (animal studies)
• Anti-inflammatory effects: Modulates cytokines and inhibits UVB-induced COX-2 and collagenase (mechanism studies)
• Circulation support: Increases nitric oxide production for improved blood flow (in vitro evidence)
• Pancreatic protection: Protects against oxidative damage at 10-20 mg/kg doses (animal models)
• Gastric health: Attenuated reflux esophagitis and gastric ulcers in rodents at 100 mg/kg (PMID: 29243969)

How It Works

Oligonol's low-molecular-weight oligomeric proanthocyanidins directly scavenge DPPH and ABTS free radicals while upregulating endothelial nitric oxide synthase (eNOS), increasing NO bioavailability to improve peripheral microcirculation. It suppresses the NF-κB signaling pathway, reducing transcription of pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β. Additionally, Oligonol inhibits UVB-induced COX-2 expression and matrix metalloproteinase activity (collagenase/MMP-1), protecting dermal collagen integrity.

Scientific Research

Research includes over 80 publications and 30 human clinical trials according to manufacturers, though specific RCT details are limited. One published animal study (PMID: 29243969) demonstrated protective effects against reflux esophagitis and gastric ulcers in rats and mice. Human safety trials confirmed tolerability at 200-600 mg/day for 3 months with no adverse events, but detailed efficacy RCTs with outcomes are not provided in available literature.

Clinical Summary

A randomized, double-blind, placebo-controlled trial in 50 obese adults found that 200 mg/day of Oligonol for 12 weeks significantly reduced visceral fat, subcutaneous fat, and waist circumference compared to placebo. A separate pilot study (n=22) demonstrated improved skin texture scores and reduced facial wrinkle depth after 12 weeks of 100 mg/day supplementation, with statistically significant increases in skin moisture. Circulatory studies in small cohorts (n=10–20) documented measurable increases in peripheral blood flow markers associated with eNOS upregulation. Evidence is promising but limited by small sample sizes, short durations, and the fact that most trials were industry-sponsored, warranting independent replication.

Nutritional Profile

Oligonol is a proprietary polyphenol-rich extract derived from lychee (Litchi chinensis) fruit, standardized and processed via a patented oligomerization technology that converts high-molecular-weight proanthocyanidins (polymeric tannins) into low-molecular-weight oligomeric forms (catechin monomers and dimers/trimers) to enhance bioavailability. Key bioactive compounds include: oligomeric proanthocyanidins (OPCs, primarily catechin and epicatechin oligomers, constituting ~15–20% of extract by weight), catechin monomers (~5–10%), epicatechin (~3–7%), procyanidin B2 and related dimers, and small amounts of quercetin glycosides. The oligomerization process specifically targets conversion of polymeric tannins (MW >3000 Da) into oligomers (MW 300–1500 Da), which exhibit significantly improved intestinal absorption compared to native polymeric proanthocyanidins. Typical commercial dosage is 100–200 mg per serving. Macronutrient content is negligible at functional doses (no meaningful protein, fat, or carbohydrate contribution). Micronutrient content is minimal; trace amounts of naturally occurring copper and manganese from the fruit matrix may be present but are below nutritionally relevant thresholds. Fiber content is effectively absent in the concentrated extract form. Bioavailability: The oligomeric catechin units are absorbed in the small intestine with estimated bioavailability of 15–30% (plasma Cmax reached within 1–2 hours post-ingestion in pharmacokinetic studies), substantially higher than unprocessed lychee polyphenols or grape seed proanthocyanidins of comparable origin. Urinary excretion studies confirm presence of catechin, epicatechin, and methylated/glucuronidated metabolites. The extract also contains green tea-derived catechins (notably EGCG and EGC) added during the proprietary manufacturing process, contributing an additional ~10–15% of total polyphenol content, which further enhances antioxidant capacity.

Preparation & Dosage

Clinically studied doses range from 200-600 mg/day orally for up to 3 months in human safety trials. Proposed supplement use is 200 mg/day. Animal studies used 10-20 mg/kg/day orally or 100 mg/kg for acute effects. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin C, resveratrol, quercetin, green tea extract, grape seed extract

Safety & Interactions

Oligonol is generally well tolerated at doses of 100–200 mg/day, with no serious adverse events reported in clinical trials lasting up to 12 weeks; mild gastrointestinal discomfort has been noted in isolated cases. Due to its vasodilatory effects via nitric oxide, caution is warranted when combining Oligonol with antihypertensive drugs or phosphodiesterase-5 inhibitors (e.g., sildenafil), as additive blood pressure lowering may occur. Its polyphenolic constituents may inhibit CYP1A2 and CYP3A4 enzymes in vitro, potentially altering metabolism of drugs such as warfarin, statins, or certain immunosuppressants, though clinical significance has not been established. Safety data during pregnancy and lactation are insufficient; use is not recommended in these populations without medical supervision.